Printer Friendly

IVAX ANNOUNCES DISTRIBUTION AGREEMENT WITH E. MERCK

 IVAX ANNOUNCES DISTRIBUTION AGREEMENT WITH E. MERCK
 MIAMI, Dec. 2 /PRNewswire/ -- IVAX Corporation (AMEX: IVX)


announced today that its subsidiary Diamedix Corporation granted E. Merck non-exclusive worldwide distribution rights to Diamedix' enzyme immunoassay test kits and fully automated instrumentation for reading and calculating the results of such diagnostic tests. E. Merck shall have the right to sell the products and instrumentation provided by Diamedix under E. Merck's own private label.
 Commenting on the distribution arrangement with E. Merck, Dr. Joseph Giegel, president of Diamedix said, "We are extremely pleased to establish this collaboration with E. Merck, one of the leading companies in the diagnostics industry. E. Merck's distribution of an important segment of Diamedix' product line worldwide will enhance Diamedix' marketing and distribution efforts for its products and, in particular, will increase Diamedix' penetration of the international market."
 E. Merck is a general partnership headquartered in the Federal Republic of Germany and a part of the Merck-Group, a globally active group of companies engaged in the chemicals and pharmaceutical industries.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company owned 50 percent by Baker Cummins Pharmaceuticals and 50 percent by Union Carbide Corporation; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 12/2/91
 /CONTACT: Phillip Frost, M.D., chairman of the board and chief executive officer of IVAX Corporation, 305-590-2206/
 (IVX) CO: IVAX Corporation; E. Merck ST: Florida IN: MTC SU:


JJ-MR -- FL003 -- 8258 12/02/91 10:05 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 1991
Words:327
Previous Article:MICHIGAN HOME SALES UP IN OCTOBER
Next Article:WPP GROUP APPOINTS NEW NON-EXECUTIVE DIRECTOR
Topics:


Related Articles
IVAX ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH BI
IVAX TO ACQUIRE MCGAW
IVAX CORPORATION AND ZENITH LABORATORIES, INC. ANNOUNCE COMPLIANCE WITH FTC REQUEST
EM INDUSTRIES, INC., THE U.S. AFFILIATE OF E. MERCK, DARMSTADT, GERMANY, AGREES TO ACQUIRE ADDITIONAL OWNERSHIP IN VWR CORPORATION
IVAX to Expand License of Its Breath Activated Inhaler to Glaxo Wellcome
Bergen Brunswig and IVAX Sign $3.2 Billion Definitive Merger Agreement
B. Braun Melsungen AG To Acquire McGaw, Inc. From IVAX Corporation
IVAX and Bergen Brunswig Settle Litigation
Forest Laboratories and Lundbeck Enter Into Settlement Agreement With Alphapharm Related to Lexapro Patent Litigation.
Forest Laboratories and Lundbeck enter into settlement agreement with Alphapharm related to Lexapro patent litigation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters